secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALVELLA THERAPEUTICS, INC. (PVLA)
CIK:        0001583648
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001193125-26-133332
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palvella reports FY2025 net loss $41.7M; Phase 3 SELVA success paves path to NDA in H2 2026
--------------------------------------------------------------------------------

- Net loss $41.7M ($3.71 per share) vs $17.4M ($7.83) in FY2024; R&D $22.8M, G&A $15.8M.
- Cash $58M at Dec 31; pro forma cash ~$274M after $230M oversubscribed equity offering closed Feb 2026.
- Phase 3 SELVA for microcystic LMs met primary endpoint (p<0.001); NDA submission on track for H2 2026.
- Phase 3 trial for cutaneous venous malformations planned H2 2026; Phase 2 for angiokeratomas in Q2 2026.
- Company to announce fourth QTORIN rapamycin indication and third platform product in H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583648/000119312526133332/0001193125-26-133332-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583648/000119312526133332/pvla-20260331.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-133332

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer